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predisposing factors [15,16]. The most common forms
of presentation have been rhinocerebral, pulmonary,
cutaneous and disseminated forms. Characteristically,
there is a high mortality rate; in fact, we only found
three reports of survival.
Systemic amphotericin B is the drug of choice. It
is recommended to start with maximal doses from the
beginning, so this mucormycosis would be an excellent
indication for lipid-based preparations. In our case we
started with a dose of 0.7 mg/kg/day because renal
function was deteriorating. But this was obviously
inadequate, as the patient state deteriorated, and he
finally died before we could increase the total dosage
of antifungal. Species of Absidia have been shown to be
susceptible in vitro to most antifungal agents, and there
is a report of three patients with mucormycosis
infection who have been effectively treated with
fluconazole [17].
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Subinhibitory concentrations of gentamicin reduce
production of listeriolysin. the main virulence factor of
Listeria monocytogenes
Clin Microbiol Infect 1997; 3: 270-272
The facultatively intracellular Gram-positive rod Listeria
monocytogenes is the causative agent of severe infections
in humans and animals, e.g. sepsis and meningo-
encephalitis. The treatment of choice is ampicillin in
combination with gentamicin [1]. Because of poor
penetration through the blood-brain barrier and into
the cytoplasm ofcells where the listeriae multiply, these
antibiotics are likely to reach concentrations below the
levels obtained in the blood at the site of infection.
Certain antibiotics are able to retard growth of
bacteria at concentrations below the minimal inhibi-
tory concentration assessed visually. In addition, some
antibiotics are capable of selectively inhibiting the
production of virulence factors by pathogenic bacteria
[2]. Ampicillin has recently been shown to reduce the
production of listeriolysin [3]. Listeriolysin is an
essential virulence factor of L. monocytogenes because
it enables the bacterium to reach the cytoplasm of
infected cells, and to start multiplication [4].
Inhibition of the production of listeriolysin could
also contribute to the therapeutic action of gentamicin
on human listeriosis. Therefore, the effect of genta-
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Figure 1 Effect of gentamicin on the B-galactosidase activity of L. monocytogenes EGD carrying a listeriolysin :
B-galactosidase fusion (.a.) or a streptococcal protease: (B-galactosidase fusion (.) expressed as relative light units (RLU) in
concentrations below the minimal inhibitory concentration (0.125 mg/L) that did not affect growth. Each point represents
the mean value ± standard deviation of the mean of the bacterial sediments of four broths. The growth control contained no
antibiotic.
micin in subinhibitory concentrations on the expression
of this virulence factor was determined.
This was done as previously described [3], using an
assay measuring the hemolytic activity in the culture
supernatants of L. monocytogenes EGD with and without
the plasmids containing the ~-galactosidase fusions and
measuring the activity of the listeriolysin promoter
contained on a plasmid fused to the lacZ gene of
Escherichia coli. This allowed the measurement of the
activity of the listeriolysin promoter as p-galactosidase
activity in the transformed strain. The expression of??
galactosidase from this promoter was compared with
that of a plasmid contained in L. monocytogenes EGD
harboring the promoter of a streptococcal protease
fused at the same EcoRI site to the lacZ gene.
Subinhibitory concentrations of gentamicin were
able to suppress the expression of p-galactosidase from
the listeriolysin promoter in concentrations that did not
affect growth or the expression of p-galactosidase
from the streptococcal promoter (Figure 1). Therefore,
gentamicin is able to selectively suppress the production
of this virulence factor. Because gentamlcm inhibits
bacterial protein synthesis by binding to the ribosome,
this action might be due to a selective suppression of
the translation of mRNAs deriving from the virulence
gene itself or from the regulatory gene pifA, whose
product regulates the production of listeriolysin and
several other virulence factors of L. monocytogenes [4].
In contrast to the ~-galactosidase assay, the
reduction of the hemolytic activity of culture super-
natants of the wild-type strains and the transformed
strains was not significant. This may be explained by
the fact that in contrast to ~-galactosidase, listeriolysin
is rapidly inactivated at the incubation temperature of
37°C ([5] and own unpublished data), which may have
led to greater standard deviations in this assay that make
it difficult to demonstrate minor effects on listeriolysin
production.
In conclusion, subinhibitory concentrations of
gentamicin that do not affect growth are able to reduce
the production of an essential virulence factor of L.
monocytogenes. In combination with a similar effect of
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ampicillin [3], this might contribute to the therapeutic
action of the two antibiotics in human listeriosis.
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Circumventing antibiotic resistance in specialized hospital
units
Response to a Letter from W H Heizmann (Clin Microbiol
Irifect 1997; 3: 133-4)
Clin Microbiol Infect 1997; 3: 272
Heizmann [1] is to be congratulated for his excellent
approach to antibiotic utilization which should enhance
appropriate and judicious use of antibiotics in his
hospital. Such individually structured regimens are
really the 'gold standard' to which everyone should
aspire. Unfortunately, many hospitals are not fortunate
enough to have the expertise required for this approach
nor do they have sufficient staff to devote to this
pursuit. Thus, alternative approaches for the less than
optimally staffed hospital need to be considered. One
alternative (of many possibilities) would be cycling.
Several items concerning the cycling scheme we
proposed [2] need clarification. First, empiric therapy
does not refer to a set regimen applied blindly. Rather,
it refers to therapy administered during a finite (and
hopefully short) time interval during which the precise
etiology of the infection is unknown. This therapy
is still selected utilizing information relating to those
five factors listed by Heizmann as components of
'calculated chemotherapy' [1). For most patients in a
specialized unit of the hospital, since they share similar
risk factors for infection and the same hospital
microbial environment, the empiric regimen would be
similar, but not always identical. Secondly, to predict
that multidrug resistant pathogens will emerge in an
area of the hospital using a cycling scheme is to ignore
the basic concept of the cycle. The cycle is to be
changed prior to the time that resistance to drugs in the
current phase of the cycle appears. If resistance appears,
then the time of the phase of use of those drugs in the
cycle needs to be shortened when their phase comes
around again. If resistance has not disappeared when
their phase comes around again, the drugs should be
dropped from the cycle until resistance disappears and
alternative drugs should be inserted into the cycle.
Thirdly, staffconfusion as to which portion of the cycle
is the current regimen should not be a problem.
Virtually every hospital now has individuals who
monitor drug utilization. This monitoring ranges from
formulary issues, to therapeutic drug monitoring, to
potential drug interactions. Thus, the mechanism is
already in place for monitoring antibiotics used in a
cycling scheme.
As we noted, any approach to therapy that reduces
the total amount of a specific antibiotic utilized in a
given environment should reduce resistance to that
drug [2]. Cycling is only one of a large number of
possibilities. Heizmann [1] has suggested a second
excellent approach. Each hospital needs to assess
antibiotic utilization and define what approach is most
appropriate and practical for its special care units.
Careful, prospective trials of various approaches should
be encouraged. It is high time that we try to prevent
resistance, rather than try to deal with it once it has
been encountered. We hope to be more successful with
the former than we have been with the latter.
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